Winkelmann BR - Search Results

1

The significance of genetic polymorphisms in modulating the response to lipid-lowering drugs.

Hoffmann MM, Winkelmann BR, Wieland H, März W. Hoffmann MM, et al. Among authors: winkelmann br. Pharmacogenomics. 2001 May;2(2):107-21. doi: 10.1517/14622416.2.2.107. Pharmacogenomics. 2001. PMID: 11368750 Review.

2

Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy.

Winkelmann BR, Hoffmann MM, Nauck M, Kumar AM, Nandabalan K, Judson RS, Boehm BO, Tall AR, Ruaño G, März W. Winkelmann BR, et al. Pharmacogenomics J. 2003;3(5):284-96. doi: 10.1038/sj.tpj.6500195. Pharmacogenomics J. 2003. PMID: 14583798

3

Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study.

Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, Böhm BO, März W. Winkler K, et al. Among authors: winkelmann br. Circulation. 2005 Mar 1;111(8):980-7. doi: 10.1161/01.CIR.0000156457.35971.C8. Epub 2005 Feb 14. Circulation. 2005. PMID: 15710755

4

Association of the single nucleotide polymorphism rs599839 in the vicinity of the sortilin 1 gene with LDL and triglyceride metabolism, coronary heart disease and myocardial infarction. The Ludwigshafen Risk and Cardiovascular Health Study.

Kleber ME, Renner W, Grammer TB, Linsel-Nitschke P, Boehm BO, Winkelmann BR, Bugert P, Hoffmann MM, März W. Kleber ME, et al. Among authors: winkelmann br. Atherosclerosis. 2010 Apr;209(2):492-7. doi: 10.1016/j.atherosclerosis.2009.09.068. Epub 2009 Oct 2. Atherosclerosis. 2010. PMID: 19837406

5

The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction.

Nauck M, Winkelmann BR, Hoffmann MM, Böhm BO, Wieland H, März W. Nauck M, et al. Among authors: winkelmann br. J Mol Med (Berl). 2002 Aug;80(8):507-13. doi: 10.1007/s00109-002-0354-2. Epub 2002 Jun 21. J Mol Med (Berl). 2002. PMID: 12185451

6

C(-260)T polymorphism in the promoter of the CD14 gene is not associated with coronary artery disease and myocardial infarction in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.

Nauck M, Winkelmann BR, Hoffmann MM, Böhm BO, Wieland H, März W. Nauck M, et al. Among authors: winkelmann br. Am J Cardiol. 2002 Dec 1;90(11):1249-52. doi: 10.1016/s0002-9149(02)02845-x. Am J Cardiol. 2002. PMID: 12450609 No abstract available.

7

Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease.

Winkelmann BR, März W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J; LURIC Study Group (LUdwigshafen RIsk and Cardiovascular Health). Winkelmann BR, et al. Pharmacogenomics. 2001 Feb;2(1 Suppl 1):S1-73. doi: 10.1517/14622416.2.1.S1. Pharmacogenomics. 2001. PMID: 11258203 Review.

8

The serotonin transporter gene polymorphism is not associated with smoking behavior.

Trummer O, Köppel H, Wascher TC, Grünbacher G, Gutjahr M, Stanger O, Ramschak-Schwarzer S, Boehm BO, Winkelmann BR, März W, Renner W. Trummer O, et al. Among authors: winkelmann br. Pharmacogenomics J. 2006 Nov-Dec;6(6):397-400. doi: 10.1038/sj.tpj.6500389. Epub 2006 May 16. Pharmacogenomics J. 2006. PMID: 16702982

9

Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study).

Hoffmann MM, Winkler K, Renner W, Winkelmann BR, Seelhorst U, Wellnitz B, Boehm BO, März W. Hoffmann MM, et al. Among authors: winkelmann br. J Thromb Haemost. 2009 Jan;7(1):41-8. doi: 10.1111/j.1538-7836.2008.03216.x. Epub 2008 Oct 31. J Thromb Haemost. 2009. PMID: 18983494 Free article.

10

Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study).

Winkler K, Hoffmann MM, Winkelmann BR, Friedrich I, Schäfer G, Seelhorst U, Wellnitz B, Wieland H, Boehm BO, März W. Winkler K, et al. Among authors: winkelmann br. Clin Chem. 2007 Aug;53(8):1440-7. doi: 10.1373/clinchem.2007.086298. Epub 2007 Jun 15. Clin Chem. 2007. PMID: 17573419

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

191 results

Search Page